Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael W Schuster

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|October 13, 2009
Report of a pilot, double-blind, placebo-controlled study of megestrol acetate in elderly dialysis patients with cachexiaShing-Shing Yeh, Mozhdeh Marandi, Henry C Thode, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 26, 2006
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategyTsiporah Shore, John Harpel, Michael W Schuster, et al.
Journal of Adolescent and Young Adult Oncology|November 30, 2018
Illness Uncertainties Tied to Developmental Tasks Among Young Adult Survivors of Hematologic CancersAliza A Panjwani, Amanda Mía Marín-Chollom, Ian Z Pervil, et al.
Experimental Hematology|September 13, 2002
The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantationMichael W Schuster, Roy Beveridge, Debra Frei-Lahr, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 22, 2007
Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplantMichael W Schuster, Tsiporah B Shore, John G Harpel, et al.
Annals of Hematology|February 4, 2026
Burixafor, a CXCR4 inhibitor with a differentiated kinetics profile: results of a phase 2 study for rapid cell mobilization in multiple myeloma and lymphoma patients undergoing transplantDevki D Sukhtankar, Pina M Cardarelli, Bita Jalilizeinali, et al.
British Journal of Haematology|September 4, 2009
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myelomaDan T Vogl, Edward A Stadtmauer, Paul G Richardson, et al.
British Journal of Haematology|November 7, 2008
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX studyStephanie J Lee, Paul G Richardson, Pieter Sonneveld, et al.
American Journal of Hematology|April 4, 2017
A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemiaHagop M Kantarjian, Michael W Schuster, Nitin Jain, et al.
British Journal of Haematology|August 21, 2008
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaSagar Lonial, Paul G Richardson, Jesús San Miguel, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|October 13, 2009
Report of a pilot, double-blind, placebo-controlled study of megestrol acetate in elderly dialysis patients with cachexiaShing-Shing Yeh, Mozhdeh Marandi, Henry C Thode, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 26, 2006
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategyTsiporah Shore, John Harpel, Michael W Schuster, et al.
Journal of Adolescent and Young Adult Oncology|November 30, 2018
Illness Uncertainties Tied to Developmental Tasks Among Young Adult Survivors of Hematologic CancersAliza A Panjwani, Amanda Mía Marín-Chollom, Ian Z Pervil, et al.
Experimental Hematology|September 13, 2002
The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantationMichael W Schuster, Roy Beveridge, Debra Frei-Lahr, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 22, 2007
Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplantMichael W Schuster, Tsiporah B Shore, John G Harpel, et al.
Annals of Hematology|February 4, 2026
Burixafor, a CXCR4 inhibitor with a differentiated kinetics profile: results of a phase 2 study for rapid cell mobilization in multiple myeloma and lymphoma patients undergoing transplantDevki D Sukhtankar, Pina M Cardarelli, Bita Jalilizeinali, et al.
British Journal of Haematology|September 4, 2009
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myelomaDan T Vogl, Edward A Stadtmauer, Paul G Richardson, et al.
British Journal of Haematology|November 7, 2008
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX studyStephanie J Lee, Paul G Richardson, Pieter Sonneveld, et al.
American Journal of Hematology|April 4, 2017
A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemiaHagop M Kantarjian, Michael W Schuster, Nitin Jain, et al.
British Journal of Haematology|August 21, 2008
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaSagar Lonial, Paul G Richardson, Jesús San Miguel, et al.
Pageof 4